| 2010-04-19: |
Stallergenes: Positive Results for Oralair( R ) Phase III Trial in the USA
Antony, France, April 19, 2010 ( PRN/ots ) - Stallergenes S.A. today announced the first results of a phase III clinical trial ( VO61.08 ) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair( R ). This phase III study is the first clinical study in (...) |
| 2010-04-15: |
Growing Threat From Potentially Lethal Diseases Highlighted at Meeting of Global Experts
New York, April 15, 2010 ( PRN/ots ) - As experts from around the world met in New York this week they discussed the need for greater understanding of the threat posed by ticks, fleas and sand flies. Leading scientists called on veterinarians and dog - (...) |
| 2010-04-06: |
Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban
Tokyo, April 6, 2010 ( PRN/ots ) - Daiichi Sankyo Company, Limited announced today that it has submitted a New Drug Application to the Ministry of Health, Labor and Welfare in Japan seeking approval of the anticoagulant, edoxaban, for the prevention of venous thromboembolism ( VTE ) after (...) |
| 2010-03-31: |
Cellvax Expands its Preclinical Service Offers by Moving to a New Laboratory Facility With an Access to Large Animals and a Number of New Technical Plat - Forms
Paris, March 31, 2010 ( PRN/ots ) - Cellvax is a French service company which provides complete in vitro & in vivo preclinical innovating services allowing to accelerate the drug development process for unmet needs related with severe human diseases, mainly in oncology field. Cellvax was (...) |
| 2010-03-30: |
Sanofi - aventis: Multaq( R ) Receives Positive Recommendation by NICE in New Appraisal Consultation Document
Paris, March 30, 2010 ( PRN/ots ) - Sanofi - aventis announced today that the National Institute for Health and Clinical Excellence ( NICE ) in England and Wales, has just published a new appraisal consultation document ( ACD )[1] for Multaq( R ) ( dronedarone ) indicating its intention to recommend Multaq( R ) use (...) |
| 2010-03-24: |
Agendia Launches BluePrint( TM ) Expanding Breast Cancer Product Offering
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint( R ), and TargetPrint( TM ), has been expanded with BluePrint ( TM ) to report important additional (...) |
| 2010-03-23: |
Hyglos GmbH - New Reliable and Sensitive Method for Direct Endotoxin Detection
Munich, Germany ( na Originaltextservice ) - Hyglos GmbH introduces a ground - breaking solution for pharmaceutical and biotechnological endotoxin - testing based on its proprietary phage - ligand technology. Bacterial endotoxin technology that uses bacteriophage - derived components has the potential to efficiently detect lipopolysaccharides ( LPS ) contaminations (...) |
| 2010-03-19: |
Levact( R ) ( bendamustine ) Recommended for Approval in Europe for Treating Blood Cancers
Cambridge, England, March 19, 2010 ( PRN/ots ) - Mundipharma announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion recommending that marketing authorisations can be granted in Germany and the following Member (...) |
| 2010-03-19: |
Tarceva Receives Positive Opinion in Europe for Maintenance Treatment of Advanced Lung Cancer
Basel, Switzerland, March 19, 2010 ( PRN/ots ) - Roche ( SIX: RO, ROG; OTCQX: RHHBY ) today announced that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a positive opinion for use of Tarceva( R ) ( erlotinib ) as a maintenance therapy for people with advanced (...) |
| 2010-03-17: |
Agendia to Play Pivotal Role in ISPY - 2 Trial for Breast Cancer
HUNTINGTON BEACH, California and AMSTERDAM, March 17, 2010 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I - SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research (...) |
| 2010-03-15: |
New ANTEK MultiTek[TM] Introduced - Provides Fast, All - in - One Testing for Sulfur, Nitrogen, Halides
Houston, Texas, USA ( na Originaltextservice ) - PAC officially announces the introduction of the ANTEK MultiTek[TM] testing system for the fast, accurate detection of sulfur, nitrogen, and halides. "MultiTek[TM] is the only instrument on the market that combines testing for sulfur, nitrogen, (...) |
| 2010-03-15: |
New AC CNS SIMDIS Analyzers for Fast and Simultaneous Hydrocarbon, Nitrogen, and Sulfur Testing
Rotterdam, The Netherlands ( na Originaltextservice ) - PAC officially announces the introduction of two AC Analytical Controls CNS Simulated Distillation systems for fast and accurate distribution information of Hydrocarbon, Nitrogen, and Sulfur. The AC CNS SIMDIS analyzers contribute to optimizing refining operations by precisely (...) |
| 2010-03-15: |
Telstar is exhibiting the first minibioreactors' system allowing multiple simultaneous cell culture trials in analytica
Terrassa, Spain ( na Originaltextservice ) - Telstar has introduced the first minibioreactors' system allowing multiple simultaneous cell culture trials for the pharmaceutical and biotechnological market. This innovative equipment, with a new line of BioSafety Cabinets Class II and the latest generation of Laboratory (...) |
| 2010-03-10: |
Chronic Kidney Disease and Diabetes - Major Risk Factors Amongst Europe's Population to Be Urgently Addressed
Strasbourg, France, March 10, 2010 ( PRN/ots ) - The European Kidney Health Alliance ( EKHA ) and World Kidney Day ( WKD ) organisations today call for European Union ( EU ) support. Early awareness, identification and treatment of chronic kidney disease ( CKD ) and its associated diseases, including diabetes - the leading cause (...) |
| 2010-03-09: |
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
ABBOTT PARK, Illinois and REDWOOD CITY, California, March 9, 2010 ( PRN/ots ) - - Abbott and Facet Biotech Corporation announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early - and mid - stage pharmaceutical pipeline. Abbott will acquire Facet for US$27 per share in (...) |
| 2010-03-09: |
Kimble Chase announces the availability of a new line of laboratory glassware
New Jersey, USA ( na Originaltextservice ) - Kimble Chase, a leader in the scientific laboratory glassware industry, is pleased to announce the introduction of its ValueWare® line of products. ValueWare® is designed from ISO and ASTM standards and is characterized by a unique combination (...) |
| 2010-03-09: |
The Pediatric Dengue Vaccine Initiative Introduces www.DengueWatch.org - a News hub for Tracking Dengue Fever Epidemics Worldwide
Seoul, March 9, 2010 ( PRN/ots ) - PDVI ( Pediatric Dengue Vaccine Initiative ), a program of the International Vaccine Institute ( IVI ) funded by the Bill & Melinda Gates Foundation, announces today the launch of http://www.denguewatch.org, a news hub for tracking dengue fever epidemics worldwide. Breaking (...) |
| 2010-03-02: |
Twenty - Five Years of HIV Blood Testing Helped to Positively Transform Global Health Crisis
Abbott Park, Illinois, March 2, 2010 ( PRN/ots ) - Imagine delaying a life - saving surgery or being afraid to receive or donate blood for fear of contracting HIV ( http://www.who.int/hiv/en/ ). It seems unbelievable today, but twenty - five years ago, this was (...) |
| 2010-02-22: |
Retacrit( TM ) to be the 1st Biosimilar Epoetin to Achieve Subcutaneous Licence in Renal Patients
London, February 22, 2010 ( PRN/ots ) - Hospira announced today that the European Committee for Medicinal Products for Human Use ( CHMP ) has recommended for approval the administration of Retacrit ( epoetin zeta ) subcutaneously in the nephrology setting. This provides an alternative option to intravenous ( IV ) delivery (...) |
| 2010-02-22: |
In the Netherlands 250.000 children are every year infested by head lice
Hoofddorp ( na Originaltextservice ) - - Bildmaterial ist abrufbar unter http://www.presseportal.de/galerie.htx?type=obs - In the Netherlands every year 250.000 children are infested by head lice. "Mummy, mummy, my head itches", the children say - by combing their hair the parasites (...) |
| 2010-02-16: |
Bluestar Silicones Launches a New Range of Silbione( R ) TCS 7560 & 7561 Elastomers for Lingerie, Support Stockings and Medical Textile Applications
Lyon, France, February 16, 2010 ( PRN/ots ) - Bluestar Silicones is launching a new line of TCS 7560 and TCS 7561 Silbione( R ) products designed for the elastic band market for lingerie and medical applications ( support stockings and medical equipment ). These two new silicone elastomers have (...) |
| 2010-02-16: |
Abbott Completes Acquisition of Solvay Pharmaceuticals
Abbott Park, Illinois, February 16, 2010 ( PRN/ots ) - Abbott today announced that it has completed its EUR 4.5 billion ( US$6.2 billion ) acquisition of Belgium - based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key (...) |
| 2010-02-11: |
Biosign Certified for Non - invasive Blood Glucose Monitoring
Toronto ( PRN/ots ) - Biosign Technologies Inc. ( CNSX: BIO ) ( "Biosign" or the "Company" ) today announced it has been assessed and certified as meeting the requirements of ISO 9001:2008, ISO 13485 - 2003, and Directive 93/42/EEC ( "CE Mark" ) for automated wrist blood pressure (...) |
| 2010-02-09: |
Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that it has received the Clinical Laboratory Permit from the New York State Department of Health. The New York State permit allows the company to receive (...) |
| 2010-02-03: |
Daiichi Sankyo initiates largest single, double - blind, randomized, Phase III trial for treatment and prevention of recurrent venous thromboembolism
Tokyo, Japan and Edison, N.J. ( na Originaltextservice ) - First Patient Randomized and Dosed in New Trial with Factor Xa Inhibitor, Edoxaban Daiichi Sankyo Company, Limited ( TSE: 4568 ), announced today that it has initiated a new large - scale pivotal Phase III trial for edoxaban, (...) |
| 2010-02-01: |
First Treatment to Improve Survival in 20 Years
Osaka, Japan and London ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( "Takeda" ) and Takeda Pharmaceuticals Europe Limited ( "TPEU" ), its wholly owned subsidiary for oversight of pan - European sales and marketing, jointly announced today that Mepact( R ) ( mifamurtide )( 1 ), the first new treatment in 20 years to improve survival (...) |
| 2010-02-01: |
Cephalon, Inc. Announces Agreement to Acquire Mepha AG
FRAZER, Philadelphia, AESCH, Switzerland and MAISONS ALFORT, France, February 1 ( PRN/ots ) - - Cephalon, Inc. announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately - held, Swiss - based pharmaceutical company. Mepha has specific expertise in innovative dosage (...) |
| 2010-01-25: |
AMP Supports the Creation of a National Immunization Technical Advisory Group in Côte d'Ivoire
Paris ( PRN/ots ) - On January 15, the Minister of Health and Hygiene of Côte d'Ivoire, Dr. Rémi Allah Kouadio, presided over a ceremony to mark the launch of a National Immunization Technical Advisory Group ( NITAG ) named "Côte d'Ivoire National Committee of Independent Experts for (...) |
| 2010-01-21: |
Abbott to Suspend Marketing of Obesity Medicine Sibutramine in European Union Countries
Abbott Park, Illinois ( PRN/ots ) - Today the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) voted to recommend the suspension of marketing authorizations for all anti - obesity medicines containing sibutramine. Abbott will comply with the CHMP recommendation and (...) |
| 2010-01-21: |
New Real World Avastin Data From Over 3,200 Metastatic Colorectal Cancer Patients Confirms Survival Benefit Beyond 2 Years
Basel, Switzerland ( PRN/ots ) - New data from two large studies observing the routine use of Avastin - based therapy in more than 3,200 patients will be announced showing impressive treatment benefits in a non - selected patient population. Key findings included high rates of tumour shrinkage (...) |
| 2010-01-14: |
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Abbott Park, Illinois ( PRN/ots ) - A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment (...) |
| 2010-01-07: |
Tolerx Completes Enrollment in DEFEND - 1, A Phase 3 Type 1 Diabetes Study With Otelixizumab
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND - 1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new - onset autoimmune type 1 diabetes. (...) |
| 2010-01-06: |
New Abbott Gene - Based Test for Colorectal Cancer Receives CE Mark
Des Plaines, Illinois ( PRN/ots ) - Abbott announced today it has received CE Marking ( Conformite Europeene ) in the European Union for a new molecular diagnostic test, Abbott RealTime mS9 Colorectal Cancer, a non - invasive DNA assay that detects the methylated form of Septin 9, a (...) |
| 2010-01-05: |
New Analysis Showed Efient( R ) Cost - Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI
Tokyo and Indianapolis ( PRN/ots ) - Results from a health economic substudy of the TRITON - TIMI 38 clinical trial showed that among patients with acute coronary syndrome ( ACS ) managed with percutaneous coronary intervention ( PCI ), including stenting, treatment with Efient( R ) ( prasugrel ) compared with branded clopidogrel ( Plavix( R ) ) was (...) |
| 2010-01-04: |
Pieris Appoints a New CEO / Appointment will bring substantial deal - making expertise to the company
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG today announced the appointment of Stephen S. Yoder as CEO with immediate effect. Mr. Yoder takes over the position from interim CEO and co - founder Claus Schalper, who will remain CFO. Mr. Yoder joins (...) |
| 2009-12-22: |
Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) announced today that it has begun dosing patients in its US Phase 2 clinical trial lead by Cleveland Clinic. This trial will examine RVX - 208, Resverlogix's oral small molecule therapy for the treatment of (...) |
| 2009-12-21: |
Medicago Reports Positive Phase I Results for its Avian Flu Pandemic Vaccine
Quebec City ( PRN/ots ) - Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus - Like Particles ( VLPs ), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine (...) |
| 2009-12-18: |
Amgen Receives CHMP Positive Opinion for Prolia( TM ) ( Denosumab ) in the European Union
Thousand Oaks, California ( PRN/ots ) - Amgen Inc. today announced that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has announced a positive opinion for the marketing authorization of Prolia( TM ) ( denosumab ) for the treatment of osteoporosis in postmenopausal (...) |
| 2009-12-17: |
FDA Broadens Clearance for Agendia's MammaPrint( R )
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration ( FDA ) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA - cleared breast cancer (...) |
| 2009-12-17: |
Boehringer Ingelheim Initiates First Phase III Clinical Trial in Ovarian Cancer
Ingelheim, Germany ( PRN/ots ) - Boehringer Ingelheim announced today the initiation of a new phase III clinical trial to evaluate one of its two late - stage oncology pipeline compounds for the treatment of patients with advanced ovarian cancer. The clinical study, called LUME - Ovar - 1 (...) |
| 2009-12-05: |
Opening of First Football for Hope Centre Heralds a New Dawn for Khayelitsha
Cape Town, South Africa ( PRN/ots ) - The first Football for Hope Centre in Khayelitsha in the outskirts of Cape Town opened its doors today ( 5 December 2009 ). FIFA President Joseph S. Blatter was joined by Western Cape Premier Helen Zille, 2010 FIFA World Cup (...) |
| 2009-12-04: |
Supporting innovative pain research / EFIC - Grunenthal Grant 2009 awarded to five young scientists
Aachen ( na Originaltextservice ) - The European Federation of Chapters of the International Association for the Study of pain ( EFIC ) and the pharmaceutical company Grunenthal awarded the EFIC - Grunenthal Grant to five young European scientists. The grant will provide financial support for their (...) |
| 2009-12-01: |
Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint( R )
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, announced today that Palmetto GBA, California's Part B Medicare administrator, has established coding guidelines for the company's MammaPrint test. MammaPrint is Agendia's FDA - cleared breast cancer recurrence test, which (...) |
| 2009-12-01: |
Men, Partners and Patients in Europe United Against Prostate Cancer
Barcelona, Spain ( PRN/ots ) - - New Survey Highlights Need for Education Resources, Critical Role of Physician in Patient Communication and Importance of Maintaining Normal Lifestyle During Treatment Findings from a survey of European prostate cancer patients, presented at the 2nd European Multidisciplinary Meeting (...) |
| 2009-11-30: |
Sanofi - aventis: Multaq( R ) Approved in the European Union for Patients With Atrial Fibrillation
Paris, November 30 ( PRN/ots ) - - First New Anti - Arrhythmic Drug to be Approved in the European Union in the Last 10 Years Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today that the European Commission has granted marketing authorization for Multaq( R ) ( dronedarone - (...) |
| 2009-11-18: |
Boehringer Ingelheim and GlaxoSmithKline Back EFA's Call for Urgent Improvements in Care for People With Lung Disease This World COPD Day
Brussels, Ingelheim, Germany and London, November 18 ( PRN/ots ) - Boehringer Ingelheim and GSK, companies with a strong heritage in COPD ( chronic obstructive pulmonary disease ) and a commitment to improved patient care, have today announced their support of The European Federation of Allergy and (...) |
| 2009-11-17: |
Video: Crestor( R ) Reduced Risk of Cardiovascular Events in Women by Nearly Half in New Analysis of Jupiter Study
Orlando, Florida, November 17 ( PRN/ots ) - JUPITER, which used CRESTOR 20 mg, is the first statin study to demonstrate a reduction in the risk of cardiovascular ( CV ) events in women without established cardiovascular disease ( CVD ). In this new analysis of 6,801 women (...) |
| 2009-11-17: |
FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
Lake Zurich, Illinois, November 17 ( PRN/ots ) - - Experts to Re - examine Guidance for Platelet Testing Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has cleared (...) |
| 2009-11-16: |
Abbott Announces Positive Three - Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large - Scale International Trial
Orlando, Florida, November 16 ( PRN/ots ) - - New ABSORB EXTEND Trial to Study Performance of Revolutionary Bioabsorbable Device in Approximately 1,000 Patients Abbott ( NYSE: ABT ) today announced three - year data from the first 30 patients in the first phase of the ABSORB (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
